Olema Oncology (OLMA)

Executive Summary

Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing novel small molecule therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is a next-generation oral selective estrogen receptor degrader (SERD) and complete antagonist designed to overcome resistance to endocrine therapy in ER+/HER2- metastatic breast cancer. The company is currently enrolling the Phase 3 OPERA-01 trial evaluating palazestrant as a monotherapy versus standard of care in patients with advanced ER+/HER2- breast cancer who have previously received a CDK4/6 inhibitor. With a differentiated mechanism that blocks both AF1 and AF2 domains of the estrogen receptor, palazestrant has shown promising early efficacy and favorable tolerability. Olema believes its drug could become a foundational therapy in the ER+ breast cancer treatment landscape, potentially replacing older SERDs like fulvestrant.

Upcoming Catalysts (preview)

• H2 2026OPERA-01 Phase 3 top-line data readout40% success
• 2026Initiation of Phase 2 combination study with CDK4/6 inhibitor90% success
• 2026Update on preclinical pipeline or expansion into additional indications50% success